EUVIMEDEUVIMED entdecken
Crossref

Naringenin protects against L-NAME-induced preeclampsia and fetal developmental abnormalities via modulation of inflammation, eNOS/NO signaling, AKT/mTOR pathway, and restoring endothelial function

Rania Yahia, Rana H Abd El-Rhman, Amany M Gad, Mohamed H A Gadelmawla, Alzahraa Ahmed Elhemiely

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-026-05570-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Rania Yahia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology Egyptian Drug Authority (EDA), Formerly (NODCAR), Giza, Egypt. Hauptthemen laut MEDLINE: Flavanones, Pre-Eclampsia, Endothelium, Vascular, Anti-Inflammatory Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 91 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preeclampsia considered as multi-organ disorder involving systemic inflammation and endothelial dysfunction. Our work was designed to investigate the protective role of Naringenin (NGN) against Nω-nitro-l-arginine methyl ester (L-NAME)-induced placental damage and congenital abnormalities in a rat model of preeclampsia. Forty-five adult female albino rats (weighing 160-180 g) were randomly allocated into nine groups (n = 6 per group) and treated for a duration of 18 days. Group 1 served as the untreated control, while Group 2 received 10% DMSO as a vehicle control. Group 3 was administered L-NAME (50 mg/kg, i.p.) from 13 to 18th day of gestation to induce preeclampsia and served as the positive control. Groups 4-6 received NGN alone at doses of 10, 25, and 50 mg/kg, p.o, respectively from 10 to 18th day of gestation. Groups 7-9 received NGN at the same doses, followed one hour later by L-NAME from day 13 to 18. Fetal developmental parameters and skeletal abnormalities were evaluated on gestational day 20. Placental inflammatory markers (TNF-α, IL-1β, TGF-β), signaling proteins (AKT and mTOR), and nitric oxide metabolites (NOx) were quantified using ELISA. Endothelial nitric oxide synthase (eNOS) expression was assessed by immunohistochemistry. Pre-treatment of L-NAME-administered dams with NGN reduced fetal death and resorption rates, elevated NO levels and eNOS expression, and significantly suppressed placental inflammatory markers (TNF-α, IL-1β, TGF-β). These effects were linked to the activation of the AKT/mTOR signaling cascade. Histopathological analysis of the placenta, liver, and kidney confirmed the biochemical findings. Furthermore, NGN alleviated intrauterine growth restriction by increasing fetal weight and length, and provided protection against L-NAME-induced morphological and skeletal deformities. The protective effects of NGN against L-NAME-induced preeclampsia appear to be dose-dependent and primarily mediated through the modulation of inflammation and endothelial dysfunction, suggesting a promising approach for combating preeclampsia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FlavanonesPre-EclampsiaEndothelium, VascularAnti-Inflammatory AgentsAnimalsFemalePregnancyNG-Nitroarginine Methyl EsterTOR Serine-Threonine KinasesNitric Oxide Synthase Type IIISignal TransductionNitric OxideProto-Oncogene Proteins c-aktRatsInflammation

Stichwörter der Autor:innen

Endothelial dysfunctionInflammationL-NAMENaringeninPreeclampsia

Substanzen

naringeninNG-Nitroarginine Methyl EsterFlavanonesTOR Serine-Threonine KinasesNitric Oxide Synthase Type IIINitric OxideProto-Oncogene Proteins c-aktmTOR protein, ratNos3 protein, ratAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Pharmacology Egyptian Drug Authority (EDA), Formerly (NODCAR), Giza, Egypt.
  • Department of Pharmacology & Toxicology, Faculty of Pharmacy, Sinai University- Kantara Branch, Ismailia, Egypt.
  • Life Sciences Department, Faculty of Biotechnology, Sinai University, Kantara Branch, Ismailia, Egypt. mohamed.hassany@su.edu.eg.

Zitieren

APA

Yahia, R., Abd El-Rhman, R. H., Gad, A. M., Gadelmawla, M. H. A., & Elhemiely, A. A. (2026). Naringenin protects against L-NAME-induced preeclampsia and fetal developmental abnormalities via modulation of inflammation, eNOS/NO signaling, AKT/mTOR pathway, and restoring endothelial function. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05570-9

Vancouver

Yahia R, Abd El-Rhman RH, Gad AM, Gadelmawla MHA, Elhemiely AA. Naringenin protects against L-NAME-induced preeclampsia and fetal developmental abnormalities via modulation of inflammation, eNOS/NO signaling, AKT/mTOR pathway, and restoring endothelial function. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05570-9

BibTeX
@article{Yahia2026,
  author = {Yahia, Rania and Abd El-Rhman, Rana H and Gad, Amany M and Gadelmawla, Mohamed H A and Elhemiely, Alzahraa Ahmed},
  title = {Naringenin protects against L-NAME-induced preeclampsia and fetal developmental abnormalities via modulation of inflammation, eNOS/NO signaling, AKT/mTOR pathway, and restoring endothelial function},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-026-05570-9}
}
Kostenlos starten →